About Myriad Genetics, Inc.
https://myriad.comMyriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications.
CEO
Samraat S. Raha
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2009-03-26 | Forward | 2:1 |
| 2000-09-12 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 169
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Goldman Sachs
Buy
Raymond James
Outperform
Piper Sandler
Overweight
Wells Fargo
Equal Weight
Stephens & Co.
Equal Weight
Scotiabank
Sector Perform
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:15.15M
Value:$92.57M
BLACKROCK, INC.
Shares:14.88M
Value:$90.91M
VANGUARD GROUP INC
Shares:7.88M
Value:$48.16M
Summary
Showing Top 3 of 316
About Myriad Genetics, Inc.
https://myriad.comMyriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $205.7M ▼ | $167.1M ▼ | $-27.4M ▲ | -13.32% ▲ | $-0.29 ▲ | $-9.8M ▲ |
| Q2-2025 | $213.1M ▲ | $481M ▲ | $-330.5M ▼ | -155.09% ▼ | $-3.57 ▼ | $-315M ▼ |
| Q1-2025 | $195.9M ▼ | $163.2M ▼ | $-100K ▲ | -0.05% ▲ | $-0 ▲ | $-14.2M ▲ |
| Q4-2024 | $210.6M ▼ | $189.9M ▲ | $-42.5M ▼ | -20.18% ▼ | $-0.47 ▼ | $-23.6M ▼ |
| Q3-2024 | $213.3M | $169.8M | $-22.1M | -10.36% | $-0.24 | $-4.8M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $145.4M ▲ | $728.1M ▲ | $355.3M ▲ | $372.8M ▼ |
| Q2-2025 | $74.4M ▼ | $677.3M ▼ | $289.2M ▼ | $388.1M ▼ |
| Q1-2025 | $91.8M ▼ | $1.01B ▼ | $301.2M ▼ | $704.9M ▲ |
| Q4-2024 | $102.4M ▲ | $1.03B ▼ | $326.5M ▼ | $701.1M ▼ |
| Q3-2024 | $99.9M | $1.08B | $349.6M | $731.7M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-27.4M ▲ | $21.1M ▲ | $-6.2M ▲ | $56.2M ▲ | $71.1M ▲ | $18.3M ▲ |
| Q2-2025 | $-330.5M ▼ | $-13.6M ▲ | $-6.9M ▲ | $2.6M ▼ | $-17.3M ▼ | $-20.5M ▲ |
| Q1-2025 | $-100K ▲ | $-16.3M ▼ | $-8.3M ▼ | $13.6M ▲ | $-10.9M ▼ | $-24.6M ▼ |
| Q4-2024 | $-42.5M ▼ | $6.6M ▲ | $-5.9M ▼ | $2.1M ▲ | $2.1M ▼ | $700K ▲ |
| Q3-2024 | $-22.1M | $700K | $7.5M | $-3.1M | $8.6M | $-5.6M |
Revenue by Products
| Product | Q3-2020 | Q1-2021 | Q2-2021 | Q3-2021 |
|---|---|---|---|---|
 Diagnostics | $130.00M ▲ | $160.00M ▲ | $180.00M ▲ | $160.00M ▼ |
 Other Segments | $10.00M ▲ | $20.00M ▲ | $10.00M ▼ | $10.00M ▲ |
Revenue by Geography
| Region | Q4-2024 | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 NonUS | $20.00M ▲ | $10.00M ▼ | $10.00M ▲ | $10.00M ▲ |
 UNITED STATES | $200.00M ▲ | $190.00M ▼ | $200.00M ▲ | $180.00M ▼ |
CEO
Samraat S. Raha
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2009-03-26 | Forward | 2:1 |
| 2000-09-12 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 169
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Goldman Sachs
Buy
Raymond James
Outperform
Piper Sandler
Overweight
Wells Fargo
Equal Weight
Stephens & Co.
Equal Weight
Scotiabank
Sector Perform
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:15.15M
Value:$92.57M
BLACKROCK, INC.
Shares:14.88M
Value:$90.91M
VANGUARD GROUP INC
Shares:7.88M
Value:$48.16M
Summary
Showing Top 3 of 316